Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.
作者信息
Giuffrida Anna Chiara, Genesini Sabrina, Franchini Massimo, De Gironcoli Marzia, Aprili Giuseppe, Gandini Giorgio
机构信息
Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Italy.
出版信息
Blood Transfus. 2008 Jul;6(3):163-8. doi: 10.2450/2008.0031-07.
Abstract
摘要
相似文献
1
Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.轻度/中度甲型血友病的抑制剂：两例病例报告及文献综述
Blood Transfus. 2008 Jul;6(3):163-8. doi: 10.2450/2008.0031-07.
2
Is oral tolerance therapy possible for haemophilia with inhibitors?
Vox Sang. 2001 Jan;80(1):61-2. doi: 10.1046/j.1423-0410.2001.00007.x.
3
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.先天性血友病中因子 VIII 和 IX 抑制剂的诊断与治疗：（第4版）。英国血友病中心医生组织。
Br J Haematol. 2013 Jan;160(2):153-70. doi: 10.1111/bjh.12091. Epub 2012 Nov 15.
4
The development of pulmonary embolus in patients with haemophilia A and high-titre inhibitors - a case series and review of the literature.
Haemophilia. 2015 Mar;21(2):e134-e136. doi: 10.1111/hae.12600. Epub 2015 Jan 21.
5
Summary report of the First International Conference on inhibitors in haemophilia A.第一届甲型血友病抑制剂国际会议总结报告
Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25.
6
7
Rituximab for the treatment of high titre inhibitors in mild haemophilia A.利妥昔单抗用于治疗轻度甲型血友病中的高滴度抑制物。
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s345-7. doi: 10.2450/2013.0229-12. Epub 2013 Feb 28.
8
The incidence of inhibitors in hemophilia A and the induction of immune tolerance.
Adv Exp Med Biol. 2001;489:89-97. doi: 10.1007/978-1-4615-1277-6_8.
9
Immune tolerance to Factor VIII: the international registry data.
Adv Exp Med Biol. 1995;386:201-8. doi: 10.1007/978-1-4613-0331-2_19.
10
Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis.利妥昔单抗在先天性血友病伴抑制物患者中的免疫耐受：基于个体患者分析的系统文献综述
Haemophilia. 2008 Sep;14(5):903-12. doi: 10.1111/j.1365-2516.2008.01839.x. Epub 2008 Jul 28.
引用本文的文献
1
Haemophilia.血友病。
Nat Rev Dis Primers. 2021 Jun 24;7(1):45. doi: 10.1038/s41572-021-00278-x.
2
Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study.关于英国血友病抑制剂患者护理标准的专家意见：一项改良的德尔菲共识研究。
Ther Adv Hematol. 2021 Apr 30;12:20406207211007058. doi: 10.1177/20406207211007058. eCollection 2021.
3
Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management.轻度血友病患者的诊断和护理：临床管理的实用建议。
Blood Transfus. 2018 Nov;16(6):535-544. doi: 10.2450/2017.0150-17. Epub 2017 Nov 14.
本文引用的文献
1
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study.既往未经治疗的甲型血友病患者中抑制剂产生的治疗相关风险因素：CANAL队列研究
Blood. 2007 Jun 1;109(11):4648-54. doi: 10.1182/blood-2006-11-056291. Epub 2007 Feb 8.
2
Characteristics of inhibitors in mild/moderate haemophilia A.轻度/中度甲型血友病中抑制剂的特征
Haemophilia. 2006 Dec;12 Suppl 6:43-7. doi: 10.1111/j.1365-2516.2006.01365.x.
3
The epidemiology of factor VIII inhibitors.
Haemophilia. 2006 Dec;12 Suppl 6:23-8; discussion 28-9. doi: 10.1111/j.1365-2516.2006.01362.x.
4
Genetic risk factors for inhibitors to factors VIII and IX.凝血因子VIII和IX抑制物的遗传风险因素。
Haemophilia. 2006 Dec;12 Suppl 6:15-22. doi: 10.1111/j.1365-2516.2006.01361.x.
5
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.VIII因子和IX因子抑制剂的基本方面以及非遗传风险因素的影响。
Haemophilia. 2006 Dec;12 Suppl 6:8-13; discussion 13-4. doi: 10.1111/j.1365-2516.2006.01360.x.
6
Application of current knowledge to the management of bleeding events during immune tolerance induction.当前知识在免疫耐受诱导期间出血事件管理中的应用。
Haemophilia. 2006 Nov;12(6):591-7. doi: 10.1111/j.1365-2516.2006.01343.x.
7
Inhibitors in mild/moderate haemophilia A: an update.轻度/中度甲型血友病的抑制剂：最新进展
Thromb Haemost. 2006 Aug;96(2):113-8.
8
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.FVIII基因第22外显子中的Tyr2105Cys突变是轻度/中度A型血友病患者产生抑制物的一个风险因素。
Haemophilia. 2006 Jul;12(4):448-51. doi: 10.1111/j.1365-2516.2006.01297.x.
9
A retrospective postlicensure survey of FEIBA efficacy and safety.对活化凝血酶原复合物（FEIBA）疗效与安全性的上市后回顾性调查。
Haemophilia. 2006 Jul;12(4):352-62. doi: 10.1111/j.1365-2516.2006.01284.x.
10
Current and future approaches to inhibitor management and aversion.
Semin Thromb Hemost. 2006 Jun;32 Suppl 2:15-21. doi: 10.1055/s-2006-946910.
Zotero 插件